Current stock page

Catalysts

ABCL Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

ABCLAbCellera Biologics Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 7/10
$11.49−$0.13 (−1.12%)

Latest quote

  • Momentum
    89
  • Value
    47
  • Quality
    61
  • Risk resilience
    34
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 23, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 64/100

Momentum 89/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 12.59%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 89/100AIQ Edge 7/10 Above Peers
Beat rate
75%
6 of 8 reported periods
Average surprise
+23.7%
Across covered historical reports
Latest result
+23.8%
Nov 9, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 9, 2026—-$0.17-$0.13+23.8%$8.42M$10.64M
Aug 5, 2026—-$0.16-$0.18-9.8%$7.85M$4.05M
May 11, 2026—-$0.22-$0.14+36.4%$5.41M$8.32M
Feb 24, 2026—-$0.18-$0.03+83.3%$6.67M$44.9M
Nov 6, 2025—-$0.17-$0.19-11.8%$6.31M$8.96M
Aug 7, 2025—-$0.17-$0.12+29.4%$6.36M$17.08M
May 8, 2025—-$0.17-$0.15+11.8%$7.31M$4.24M
Feb 27, 2025—-$0.15-$0.11+26.7%$7.58M$5.05M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
12
Buy
1
Hold
12-month analyst target
$17.33
+50.86% versus current price
Based on 13 analyst observations. Targets are estimates, not predictions.
Low target
$13.00
+13.14% vs latest price
Average target
$17.33
+50.86% vs latest price
High target
$21.00
+82.77% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 23, 2027

Next known earnings or reporting date.

EPS estimate-$0.18

Current analyst expectation for the upcoming report.

Revenue estimate$7.28M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score89

Where event reaction would show up first.

AIQ score64/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
13
Average target
$17.33
Target upside
50.86%
Target range
$13.00 - $21.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
2
Neutral
3
Negative
0
seekingalpha.com · Nov 12, 2026

AbCellera Biologics Inc. 2026 Q3 - Results - Earnings Call Presentation

2026-11-12. The following slide deck was published by AbCellera Biologics Inc.

gurufocus.com · Nov 12, 2026

10% Owner Holdings Thermopylae Buys 60,565 Shares of AbCellera Biologics (ABCL)

Holdings Thermopylae, a 10% owner of AbCellera Biologics Inc (ABCL), has added to its stake in the clinical-stage biotechnology company, according to a recent S

seekingalpha.com · Nov 10, 2026

AbCellera outlines plans to initiate ABCL635 late-stage development in 2027, while citing liquidity for at least the next 3 years (NASDAQ:ABCL)

AbCellera Q3 2026 earnings insights: ABCL635 Phase II menopause data, 2027 late-stage plans, new pipeline programs, and strong liquidity.

seekingalpha.com · Nov 10, 2026

AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call Transcript

AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call November 9, 2026 5:00 PM ESTCompany ParticipantsTryn Stimart - Chief Legal Officer, Chief Compliance...

zacks.com · Nov 9, 2026

AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates

ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of +27.78% and +95.79%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Open full news and sentiment

ABCL Catalysts FAQ

What are the next catalysts for ABCL stock?

ABCL's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move ABCL stock?

Upcoming events that could move ABCL include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could ABCL's next earnings report affect the stock?

ABCL's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive ABCL stock higher?

ABCL could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt ABCL stock?

ABCL could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.